LTGO vs POM: fair value comparison
Latigo Biotherapeutics, Inc. and Pomdoctor Limited · Updated 2026-10-19
LTGO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. POM reports in CNY, so no same-currency fair-value verdict is published for it. Within Healthcare, LTGO currently ranks higher by quality score.
| LTGO | POM | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $14.00 | $0.92 |
| 12-month range | $14.00–$22.26 | $0.55–$109.62 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #288 of 301 Healthcare | #290 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: LTGO fair value analysis · POM fair value analysis